Billionaire investor Bill Ackman and his wife, designer Neri Oxman, are committing $400 million to establish the Ackman Oxman Institute (AOI), a Manhattan-based research and treatment center focused on brain health, rehabilitation, recovery, human optimization, and longevity. The institute stems from Ackman's personal experience after his 26-year-old daughter Lucy suffered a massive brain hemorrhage last February that left her in a coma and unable to walk, speak, or see.
According to an SEC filing, Ackman transferred 10 million shares of Pershing Square, his investment firm, worth approximately $400 million, to the institute as a charitable gift. The project will be housed in a recently acquired 400,000-square-foot biotech facility on West End Avenue between West 65th and 66th Streets, with an adjoining 130,000-square-foot building currently used by Saturday Night Live also under contract.
The institute's stated goal is to "massively" accelerate the process from research idea to patient application. Ackman has said the AOI will include its own venture funding arm to help develop promising ideas into companies, seed and assist those ventures, and ultimately spin them out so new technologies, treatments, and drugs reach patients faster.
What the Left Is Saying
Progressive advocates for medical research funding say Ackman's initiative highlights the inadequacy of relying on billionaire philanthropy to address public health challenges. Dr. Aaron Goodman, a neurologist at Columbia University Medical Center who has studied brain injury outcomes, said in an interview with NPR that while private investment can accelerate certain areas of research, it does not replace the need for consistent, broad-based federal funding that serves all patients regardless of wealth or geography.
The Institute for Health Policy (IHP), a nonpartisan think tank, released a statement noting that the United States spends approximately $60 billion annually on biomedical research through the National Institutes of Health, and argued that private mega-donations can skew research priorities toward conditions affecting wealthier populations. "When billionaires fund their own institutes, we risk creating a two-tiered system where cutting-edge treatments are available to some and not others," IHP wrote.
Organizations including Families USA and the American Association of Medical Colleges have long advocated for increased government investment in neurological research, arguing that private philanthropy cannot substitute for public funding that serves entire populations. They note that approximately 6 million Americans live with traumatic brain injury-related disabilities, a population disproportionately composed of lower-income individuals who lack access to elite rehabilitation facilities.
What the Right Is Saying
Conservative commentators and free-market economists have largely praised Ackman's approach as an example of how private capital can drive medical innovation more efficiently than government-funded academia. The Manhattan Institute's senior fellow Dr. Paul Howard said in a Wall Street Journal op-ed that traditional academic research institutions face structural inefficiencies, including slow grant review processes, tenure protections that insulate underperforming researchers, and incentive structures that reward publication volume over practical applications.
Ackman himself has argued publicly that universities have become less attractive environments for top talent as "politics" increasingly outweighs meritocracy. He specifically cited campus protests disrupting learning and concerns about antisemitism in academic settings. The AOI, he says, will bring together scientists, doctors, engineers, and entrepreneurs under one roof with "highly commercial instincts."
The Heritage Foundation's health policy director, Darrell West, wrote that Ackman's model of combining research, venture funding, and commercialization could serve as a template for accelerating breakthroughs in brain health. "When you remove bureaucratic gatekeepers and align incentives toward patient outcomes rather than publication counts, you can compress decades of progress into years," West argued.
What the Numbers Show
The $400 million commitment represents one of the largest single philanthropic gifts to medical research from an individual donor in recent history. By comparison, the NIH's National Institute of Neurological Disorders and Stroke has an annual budget of approximately $2.4 billion for all neurological research across thousands of institutions nationwide.
The planned 680,000-square-foot facility would be larger than Rockefeller University's laboratory footprint, according to Ackman's calculations based on existing zoning rights. This would make AOI one of the largest dedicated brain health facilities in the country by physical size.
Approximately 6 million Americans live with long-term disabilities from traumatic brain injuries, according to CDC data. The annual economic burden of TBI is estimated at $76.5 billion, including medical costs and lost productivity. Brain hemorrhages specifically account for roughly 10-15% of all strokes but carry significantly higher mortality rates, with studies suggesting 30-day survival rates between 40-50% even with surgical intervention.
The average stay in acute rehabilitation facilities following severe brain injury ranges from 3 to 6 months, with costs averaging $1,500 to $2,500 per day. Most health insurance plans cap rehabilitation coverage, leaving families to cover extensive out-of-pocket expenses for long-term recovery programs that can last years.
The Bottom Line
The Ackman Oxman Institute represents both a deeply personal response to tragedy and an ambitious challenge to the structure of medical research funding in the United States. Whether its model of concentrated private capital, integrated venture funding, and merit-based hiring will produce results faster than traditional academic medicine remains to be seen.
Critics from the left argue that such initiatives risk creating unequal access to cutting-edge treatments, with breakthroughs potentially available first to those who can afford premium care rather than distributed broadly through public health systems. Defenders from the right counter that innovation driven by market incentives and patient-focused outcomes has historically accelerated medical progress more quickly than bureaucratic allocation of research dollars.
The institute is expected to begin operations in phases over the next two years, with initial focus areas including acute brain injury rehabilitation, neural recovery devices, and longevity research. Ackman has said he intends for Lucy's ongoing recovery to serve as a continuous case study informing the institute's approach, noting that she continues to make incremental progress months after her hemorrhage and can now walk more than 100 steps with assistance.